drugset / Trial / NCT00161356

Ambisome in Liver Transplant Patients

NCT00161356

Non-randomizedSingle-groupOpen-labelPrevention

Summary

In this study we are trying to find out the amount of a drug called Ambisome in the liver, the blood, the bile and the fatty tissues of the body. This drug is approved for treatment of infections caused by fungus and is known to be effective against most of the fungal infections, which can happen after liver transplantation. By taking small pieces (less than quarter of a teaspoon) of liver and fat during the liver transplant operation, we can measure how much of the drug is concentrated in the liver. After that, we will measure the level of the drug in the blood and in the bile that comes out of a small tube which is inserted into the bile tube as a routine in all liver transplant patients. These measurements will be taken daily for a week and then weekly for another 3 weeks. We are inviting you to take part in this study in order to increase our knowledge of the behavior of this drug so that we can find the most effective treatment to prevent fungal infections in liver transplant patients.

Timeline

Start
2005-09
Primary completion
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Amphotericin B Unknown 5 mg/kg Intravenous

Indications

No indication recorded.